1: Eggan BL, McCallum SE. 18-Methoxycoronaridine acts in the medial habenula to attenuate behavioral and neurochemical sensitization to nicotine. Behav Brain Res. 2016 Jul 1;307:186-93. doi: 10.1016/j.bbr.2016.04.008. PubMed PMID: 27059333.
2: Polston JE, Pritchett CE, Sell EM, Glick SD. 18-Methoxycoronaridine blocks context-induced reinstatement following cocaine self-administration in rats. Pharmacol Biochem Behav. 2012 Nov;103(1):83-94. PubMed PMID: 22885280; PubMed Central PMCID: PMC3526685.
3: Taraschenko OD, Maisonneuve IM, Glick SD. Sex differences in high fat-induced obesity in rats: Effects of 18-methoxycoronaridine. Physiol Behav. 2011 Jun 1;103(3-4):308-14. doi: 10.1016/j.physbeh.2011.02.011. PubMed PMID: 21324333.
4: McCallum SE, Taraschenko OD, Hathaway ER, Vincent MY, Glick SD. Effects of 18-methoxycoronaridine on ghrelin-induced increases in sucrose intake and accumbal dopamine overflow in female rats. Psychopharmacology (Berl). 2011 May;215(2):247-56. doi: 10.1007/s00213-010-2132-0. PubMed PMID: 21210086; PubMed Central PMCID: PMC3790315.
5: Taraschenko OD, Maisonneuve IM, Glick SD. 18-Methoxycoronaridine, a potential anti-obesity agent, does not produce a conditioned taste aversion in rats. Pharmacol Biochem Behav. 2010 Sep;96(3):247-50. doi: 10.1016/j.pbb.2010.05.002. PubMed PMID: 20457177; PubMed Central PMCID: PMC4575503.
6: Rezvani AH, Cauley MC, Slade S, Wells C, Glick S, Rose JE, Levin ED. Acute oral 18-methoxycoronaridine (18-MC) decreases both alcohol intake and IV nicotine self-administration in rats. Pharmacol Biochem Behav. 2016 Oct 29. pii: S0091-3057(16)30194-0. doi: 10.1016/j.pbb.2016.10.010. [Epub ahead of print] PubMed PMID: 27984095.
7: Taraschenko OD, Maisonneuve IM, Glick SD. Resistance of male Sprague-Dawley rats to sucrose-induced obesity: effects of 18-methoxycoronaridine. Physiol Behav. 2011 Feb 1;102(2):126-31. doi: 10.1016/j.physbeh.2010.10.010. PubMed PMID: 20951714; PubMed Central PMCID: PMC4575504.
8: McCallum SE, Glick SD. 18-Methoxycoronaridine blocks acquisition but enhances reinstatement of a cocaine place preference. Neurosci Lett. 2009 Jul 17;458(2):57-9. doi: 10.1016/j.neulet.2009.04.019. PubMed PMID: 19442876; PubMed Central PMCID: PMC2688769.
9: Arias HR, Rosenberg A, Feuerbach D, Targowska-Duda KM, Maciejewski R, Jozwiak K, Moaddel R, Glick SD, Wainer IW. Interaction of 18-methoxycoronaridine with nicotinic acetylcholine receptors in different conformational states. Biochim Biophys Acta. 2010 Jun;1798(6):1153-63. doi: 10.1016/j.bbamem.2010.03.013. PubMed PMID: 20303928; PubMed Central PMCID: PMC3787694.
10: Taraschenko OD, Rubbinaccio HY, Maisonneuve IM, Glick SD. 18-methoxycoronaridine: a potential new treatment for obesity in rats? Psychopharmacology (Berl). 2008 Dec;201(3):339-50. doi: 10.1007/s00213-008-1290-9. PubMed PMID: 18751969; PubMed Central PMCID: PMC3787601.
11: Glick SD, Ramirez RL, Livi JM, Maisonneuve IM. 18-Methoxycoronaridine acts in the medial habenula and/or interpeduncular nucleus to decrease morphine self-administration in rats. Eur J Pharmacol. 2006 May 10;537(1-3):94-8. PubMed PMID: 16626688.
12: Silva EM, Cirne-Santos CC, Frugulhetti IC, Galvão-Castro B, Saraiva EM, Kuehne ME, Bou-Habib DC. Anti-HIV-1 activity of the Iboga alkaloid congener 18-methoxycoronaridine. Planta Med. 2004 Sep;70(9):808-12. PubMed PMID: 15386189.
13: Panchal V, Taraschenko OD, Maisonneuve IM, Glick SD. Attenuation of morphine withdrawal signs by intracerebral administration of 18-methoxycoronaridine. Eur J Pharmacol. 2005 Nov 21;525(1-3):98-104. PubMed PMID: 16289028.
14: Kuehne ME, He L, Jokiel PA, Pace CJ, Fleck MW, Maisonneuve IM, Glick SD, Bidlack JM. Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. J Med Chem. 2003 Jun 19;46(13):2716-30. PubMed PMID: 12801235.
15: Zhang W, Ramamoorthy Y, Tyndale RF, Glick SD, Maisonneuve IM, Kuehne ME, Sellers EM. Metabolism of 18-methoxycoronaridine, an ibogaine analog, to 18-hydroxycoronaridine by genetically variable CYP2C19. Drug Metab Dispos. 2002 Jun;30(6):663-9. PubMed PMID: 12019193.
16: Delorenzi JC, Freire-de-Lima L, Gattass CR, de Andrade Costa D, He L, Kuehne ME, Saraiva EM. In vitro activities of iboga alkaloid congeners coronaridine and 18-methoxycoronaridine against Leishmania amazonensis. Antimicrob Agents Chemother. 2002 Jul;46(7):2111-5. PubMed PMID: 12069962; PubMed Central PMCID: PMC127312.
17: Alper K, Bai R, Liu N, Fowler SJ, Huang XP, Priori SG, Ruan Y. hERG Blockade by Iboga Alkaloids. Cardiovasc Toxicol. 2016 Jan;16(1):14-22. doi: 10.1007/s12012-015-9311-5. PubMed PMID: 25636206.
18: Mundey MK, Blaylock NA, Mason R, Glick SD, Maisonneuve IM, Wilson VG. Pharmacological comparison of the effect of ibogaine and 18-methoxycoronaridine on isolated smooth muscle from the rat and guinea-pig. Br J Pharmacol. 2000 Apr;129(8):1561-8. PubMed PMID: 10780959; PubMed Central PMCID: PMC1571996.
19: Szumlinski KK, McCafferty CA, Maisonneuve IM, Glick SD. Interactions between 18-methoxycoronaridine (18-MC) and cocaine: dissociation of behavioural and neurochemical sensitization. Brain Res. 2000 Jul 21;871(2):245-58. PubMed PMID: 10899291.
20: Szumlinski KK, Maisonneuve IM, Glick SD. The potential anti-addictive agent, 18-methoxycoronaridine, blocks the sensitized locomotor and dopamine responses produced by repeated morphine treatment. Brain Res. 2000 May 2;864(1):13-23. PubMed PMID: 10793182.